Cargando…
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
BACKGROUND: Intradermal MVA85A, a candidate vaccine against tuberculosis, induces high amounts of Ag85A-specific CD4 T cells in adults who have already received the BCG vaccine, but aerosol delivery of this vaccine might offer immunological and logistical advantages. We did a phase 1 double-blind tr...
Autores principales: | Satti, Iman, Meyer, Joel, Harris, Stephanie A, Thomas, Zita-Rose Manjaly, Griffiths, Kristin, Antrobus, Richard D, Rowland, Rosalind, Ramon, Raquel Lopez, Smith, Mary, Sheehan, Sharon, Bettinson, Henry, McShane, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science ;, The Lancet Pub. Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178237/ https://www.ncbi.nlm.nih.gov/pubmed/25151225 http://dx.doi.org/10.1016/S1473-3099(14)70845-X |
Ejemplares similares
-
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016) -
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012) -
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
por: Riste, Michael, et al.
Publicado: (2021) -
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2019)